Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 2, 2002, Pages 121-126

  Lathia, Chetan ^a,c,d   Fleming, Gini F ^b,c,d   Meyer, Mark ^a,c,d   Ratain, Mark J ^b,c,d   Whitfield, Lloyd ^a,c,d  

^a PFIZER INC   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d BAYER CORPORATION   (United States)

Author keywords

Dosing recommendations; Pentostatin; Pharmacokinetics; Renal impairment; Toxicity

Indexed keywords

CREATININE; PENTOSTATIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INFUSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARINIZATION; HUMAN; HUMAN TISSUE; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; NEPHROTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; TIME; URINALYSIS; VALIDATION PROCESS;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; CREATININE; ENZYME INHIBITORS; FEMALE; HUMANS; KIDNEY DISEASES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; PENTOSTATIN;

EID: 0036351276     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0468-9     Document Type: Article

References (11)

1. 2′-Deoxycoformycin: Summary and future directions
2. Clinical experience with 2′-deoxycoformycin
3. Pentostatin in T-cell malignancies - A phase II trial of the EORTC Leukemia Cooperative Group
4. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations
5. Perspectives on purine analogues
6. Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias
7. Clinical pharmacokinetics of 2′-deoxycoformycin
8. Clinical pharmacology of deoxycoformycin
9. The clinical pharmacology of the adenosine deaminase inhibitor 2′-deoxycoformycin
10. Clinical and pharmacologic investigation of deoxycoformycin
11. Clinical pharmacokinetics of 2′-deoxycoformycin in renal impairment